Holen Sie sich die Stockscreener-App
1.13
0.88%
-0.01
Handel nachbörslich:
1.12
-0.010
-0.88%
Schlusskurs vom Vortag:
$1.14
Offen:
$1.18
24-Stunden-Volumen:
34,518
Relative Volume:
0.69
Marktkapitalisierung:
$4.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.87M
KGV:
-0.0286
EPS:
-39.4678
Netto-Cashflow:
$-8.76M
1W Leistung:
+10.78%
1M Leistung:
+13.00%
6M Leistung:
-26.62%
1J Leistung:
-88.13%
1-Tages-Spanne:
$1.12
$1.2173
1-Wochen-Bereich:
$1.03
$1.2173
52-Wochen-Spanne:
$0.875
$11.72
Revelation Biosciences Inc Stock (REVB) Company Profile
Firmenname
Revelation Biosciences Inc
Sektor
Branche
Telefon
650-800-3717
Adresse
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Compare REVB vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
1.13 | 4.14M | 0 | -9.87M | -8.76M | -39.47 |
VRTX
Vertex Pharmaceuticals Inc
|
523.91 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
808.05 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
866.11 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.97 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.00 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Revelation Biosciences Inc Aktie (REVB) Neueste Nachrichten
Revelation Biosciences Inc (REVB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Revelation Biosciences Inc (REVB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Revelation Biosciences Inc (REVB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Revelation Biosciences Inc (REVB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
REVB|Revelation Biosciences Inc|Price:1.050|Chg%:-0.010 - TradingKey
Revelation Biosciences Inc (REVB) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
Revelation Biosciences Inc (REVB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Revelation Biosciences Inc (REVB) Institutional Confidence - TradingKey
Revelation Biosciences Inc (REVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
REVB|Revelation Biosciences Inc|Price:1.060|Chg%:-0.030 - TradingKey
Revelation Biosciences Inc (REVB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Daily Corinthian
Three New Hires Get Revelation Biosciences Stock Awards Through 2028 - Stock Titan
Revelation Biosciences Adopts Stockholder Rights Plan to Protect Investors and Maximize Value - Minichart
Revelation Biosciences Adopts Stockholder Rights Protection Plan - TipRanks
Why Is Revelation Biosciences (NASDAQ:REVB) in Focus Today? - Kalkine Media
Revelation Biosciences Announces Adoption of Stockholder Rights Plan - ACCESS Newswire
New plan lets Revelation investors buy discounted shares if a buyer crosses 10% - Stock Titan
Revelation Biosciences (REVB) Hovers Near Support Amid Modest DeclineBollinger Expansion - dars.gov.et
REVB Q1 2026 Earnings: EPS Misses Estimates Significantly Amid No Revenue; Stock Rises 3.85%Earnings Cycle Outlook - DonanımHaber
Revelation Biosciences, Inc. Warrant 2022-10.01.27 on Revelatn Biosci Financial Disclosures & SEC Filings - TradingView
Price to sales forward of Revelation Biosciences, Inc. – NASDAQ:REVB - TradingView
Price to earnings forward of Revelation Biosciences, Inc. – NASDAQ:REVBW - TradingView
Revelation Biosciences Inc. (REVB) Holds Steady Near Support as Micro-Cap Stock Shows Slight UptickATR Trailing Stop - dars.gov.et
REVB Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock Gains 6%Analyst Consensus Shift - dars.gov.et
Revelation Biosciences (REVB) Surges 6% as Biotech Stock Tests Key Resistance LevelJelly Roll Trade - DonanımHaber
Price to earnings forward of Revelation Biosciences, Inc. – BOATS:REVBW - TradingView
Revelation Biosciences, Inc. Actuals & Estimates (NASDAQ:REVB) - TradingView
ADTX Stock Price and Chart — OTC:ADTX - TradingView
Revelation Biosciences, Inc. Actuals & Estimates (BOATS:REVB) - TradingView
REVB Q1 2026 Earnings: EPS Miss Widens Loss, No Revenue Reported as Stock DeclinesLow Growth Earnings - dars.gov.et
REVB Forecast — Price Target — Prediction for 2027 - TradingView
Revelation Biosciences Inc (REVBW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Revelation Biosciences Amends Executive Agreements and Bylaws, Announces CEO and CFO Changes – June 2026 - Minichart
Revelation Biosciences Updates Executive Contracts, Shareholder Actions - TipRanks
Revelation Biosciences updates employment agreements for CEO James Rolke and CFO Chester S. Zygmont, III - TradingView
Revelation Biosciences (NASDAQ: REVB) expands CEO/CFO protections and secures reverse split authority - Stock Titan
John Lowe, of Sayville, pleads guilty to insider trading scheme that netted $1 million in illegal profits - Newsday
Revelation Biosciences Inc (REVBW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Revelation Biosciences Inc (REVBW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Revelation Biosciences Inc (REVBW) Institutional Confidence - TradingKey
Revelation Biosciences Inc (REVBW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Revelation Biosciences Inc (REVBW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Revelation Biosciences Inc (REVBW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Revelation Biosciences Inc (REVBW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Revelation Biosciences Inc - TradingKey
Revelation Biosciences, Inc. Financial Disclosures & SEC Filings - TradingView
REVB SEC FilingsRevelation Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
REVB Q1 2026 Earnings: EPS Misses Estimates by Wide Margin; No Revenue ReportedEPS Revision Trend - newsline.com
REVB Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue StageCFO Commentary Report - newsline.com
Finanzdaten der Revelation Biosciences Inc-Aktie (REVB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.82%
1.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):